Skip to menu Skip to content Skip to footer
Professor Paul Griffin
Professor

Paul Griffin

Email: 

Overview

Background

Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.

Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.

As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.

In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.

Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

Availability

Professor Paul Griffin is:
Available for supervision
Media expert

Research impacts

While performing vital clinical and research duties, he has also devoted time to inform, educate and reassure the community via a wide range of media appearances. He has featured regularly on prominent Australian programs across television, radio, print and online including The Project, Sunrise, Today Show, A Current Affair, and internationally including Canada’s CTV and the BBC.

Works

Search Professor Paul Griffin’s works on UQ eSpace

90 works between 2005 and 2024

41 - 60 of 90 works

2019

Conference Publication

Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial

Lickliter, Jason D., Griffin, Paul, Vincent, Emmanuelle, Schuler, Armin, Harrison-Moench, Eleanor, Stahl, Michael, El Bawab, Samer, Kanceva, Radmila and Gascon, Pere (2019). Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31May - 4 June, 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.e14514

Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial

2019

Conference Publication

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

Collins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. 71st Annual Meeting of the American Academy of Neurology (AAN), Philadelphia, PA, United States, 4-10 May, 2019. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

2019

Conference Publication

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

Collins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p5.2-079

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

2019

Journal Article

DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum

Collins, Katharine A., Rueckle, Thomas, Elliott, Suzanne, Marquart, Louise, Ballard, Emma, Chalon, Stephan, Griffin, Paul, Moehrle, Joern J. and McCarthy, James S. (2019). DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 63 (4) e01837-18. doi: 10.1128/AAC.01837-18

DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum

2019

Journal Article

Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials

Manton, Kerry J., Gauld, Cassandra S., White, Katherine M., Griffin, Paul M. and Elliott, Suzanne L. (2019). Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open, 9 (1) e024224, e024224. doi: 10.1136/bmjopen-2018-024224

Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials

2018

Journal Article

Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial

Harris, Patrick N. A., Tambyah, Paul A., Lye, David C., Mo, Yin, Lee, Tau H., Yilmaz, Mesut, Alenazi, Thamer H., Arabi, Yaseen, Falcone, Marco, Bassetti, Matteo, Righi, Elda, Rogers, Benjamin A., Kanj, Souha, Bhally, Hasan, Iredell, Jon, Mendelson, Marc, Boyles, Tom H., Looke, David, Miyakis, Spiros, Walls, Genevieve, Al Khamis, Mohammed, Zikri, Ahmed, Crowe, Amy, Ingram, Paul, Daneman, Nick, Griffin, Paul, Athan, Eugene, Lorenc, Penelope, Baker, Peter ... MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2018). Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA, 320 (10), 984-994. doi: 10.1001/jama.2018.12163

Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial

2018

Journal Article

Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial

Proietto, Joseph, Malloy, Jaret, Zhuang, Dongliang, Arya, Mark, Cohen, Neale D., de Looze, Ferdinandus J., Gilfillan, Christopher, Griffin, Paul, Hall, Stephen, Nathow, Thomas, Oldfield, Geoffrey S., O'Neal, David N., Roberts, Adam, Stuckey, Bronwyn G. A., Yue, Dennis, Taylor, Kristin and Kim, Dennis (2018). Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. Diabetologia, 61 (9), 1918-1922. doi: 10.1007/s00125-018-4677-0

Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial

2018

Journal Article

Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial

Sekuloski, Silvana, Batzloff, Michael R., Griffin, Paul, Parsonage, William, Elliott, Suzanne, Hartas, Jon, O'Rourke, Peter, Marquart, Louise, Pandey, Manisha, Rubin, Fran A., Carapetis, Jonathan, McCarthy, James and Good, Michael F. (2018). Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS One, 13 (7) e0198658, e0198658. doi: 10.1371/journal.pone.0198658

Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial

2018

Journal Article

Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™)

Fernando, Germain J. P., Hickling, Julian, Jayashi Flores, Cesar M., Griffin, Paul, Anderson, Christopher D., Skinner, S. Rachel, Davies, Cristyn, Witham, Katey, Pryor, Melinda, Bodle, Jesse, Rockman, Steve, Frazer, Ian H. and Forster, Angus H. (2018). Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine, 36 (26), 3779-3788. doi: 10.1016/j.vaccine.2018.05.053

Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™)

2018

Journal Article

The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study

Woodford, John, Shanks, G Dennis, Griffin, Paul, Chalon, Stephan and McCarthy, James (2018). The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. The American Journal of Tropical Medicine and Hygiene, 98 (4), 1113-1119. doi: 10.4269/ajtmh.17-0754

The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study

2018

Conference Publication

A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer

Yamada, M., Miller, D., Lowe, M., Rowe, C., Wood, D., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J., Brandt, G., Griffin, P., Spleman, L. and Prow, T. (2018). A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer. International Investigative Dermatology (IID) Meeting, Orlando, FL, United States, 16-19 May 2018. New York, United States: Elsevier.

A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer

2017

Journal Article

Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects

Griffin, Paul, Elliot, Suzanne, Krauer, Kenia, Davies, Cristyn, Skinner, Rachel, Anderson, Christopher D. and Forster, Anguis (2017). Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects. Vaccine, 35 (48), 6676-6684. doi: 10.1016/j.vaccine.2017.10.021

Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects

2017

Journal Article

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

McCarthy, James S., Lotharius, Julie, Ruckle, Thomas, Chalon, Stephan, Phillips, Margaret A., Elliott, Suzanne, Sekuloski, Silvana, Griffin, Paul, Ng, Caroline L., Fidock, David A., Marquart, Louise, Williams, Noelle S., Gobeau, Nathalie, Bebrevska, Lidiya, Rosario, Maria, Marsh, Kennan and Mohrle, Jorg J. (2017). Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. The Lancet Infectious Diseases, 17 (6), 626-635. doi: 10.1016/S1473-3099(17)30171-8

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

2017

Journal Article

First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery

Bursle, Evan, Playford, E. Geoffrey, Coulter, Chris and Griffin, Paul (2017). First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery. Infection, Disease and Health, 22 (1), 1-5. doi: 10.1016/j.idh.2017.01.003

First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery

2017

Book Chapter

Furazolidone (furazolidine)

Doshi, Jaslyn and Griffin, Paul M. (2017). Furazolidone (furazolidine). Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. (pp. 3187-3194) edited by M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton and David L. Paterson. Boca Raton, FL United States: CRC Press. doi: 10.1201/9781315152110

Furazolidone (furazolidine)

2017

Book Chapter

Diloxanide furoate

Eisemann, Jared E. and Griffin, Paul M. (2017). Diloxanide furoate. Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. (pp. 3195-3199) edited by M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton and David L. Paterson. Boca Raton, FL United States: CRC Press. doi: 10.1201/9781315152110

Diloxanide furoate

2017

Journal Article

MALDI-TOF MS meets WGS in a VRE outbreak investigation

Schlebusch, S., Price, G. R., Gallagher, R. L., Horton-Szar, V., Elbourne, L. D. H., Griffin, P., Venter, D. J., Jensen, S. O. and van Hal, S. J. (2017). MALDI-TOF MS meets WGS in a VRE outbreak investigation. European Journal of Clinical Microbiology and Infectious Diseases, 36 (3), 1-5. doi: 10.1007/s10096-016-2824-4

MALDI-TOF MS meets WGS in a VRE outbreak investigation

2017

Book Chapter

Niclosamide

Griffin, Paul M. and McCarthy, James (2017). Niclosamide. Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. (pp. 3405-3409) edited by M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton and David L. Paterson. Boca Raton, FL United States: CRC Press. doi: 10.1201/9781315152110

Niclosamide

2016

Journal Article

Plasmodium vivax controlled human malaria infection - progress and prospects

Payne, Ruth O., Griffin, Paul M., McCarthy, James S. and Draper, Simon J. (2016). Plasmodium vivax controlled human malaria infection - progress and prospects. Trends in Parasitology, 33 (2), 141-150. doi: 10.1016/j.pt.2016.11.001

Plasmodium vivax controlled human malaria infection - progress and prospects

2016

Journal Article

Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission

Griffin, Paul, Pasay, Cielo, Elliott, Suzanne, Sekuloski, Silvana, Sikulu, Maggy, Hugo, Leon, Khoury, David, Cromer, Deborah, Davenport, Miles, Sattabongkot, Jetsumon, Ivinson, Karen, Ockenhouse, Christian and McCarthy, James (2016). Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission. PLoS Neglected Tropical Diseases, 10 (12) e0005139, e0005139. doi: 10.1371/journal.pntd.0005139

Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission

Funding

Past funding

  • 2019 - 2023
    Syphilis in pregnant women and their newborn infants in South-East Queensland 2016-202: A retrospective review of management and outcomes and evaluation of barriers to care
    Children's Health Queensland Hospital and Health Service
    Open grant

Supervision

Availability

Professor Paul Griffin is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

Contact Professor Paul Griffin directly for media enquiries about:

  • COVID-19
  • Infectious Diseases
  • microbiology
  • Vaccines

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au